{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T21:56:16Z","timestamp":1757454976925,"version":"3.37.3"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,22]],"date-time":"2020-02-22T00:00:00Z","timestamp":1582329600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,2,22]],"date-time":"2020-02-22T00:00:00Z","timestamp":1582329600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ordre des pharmaciens du Liban","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>In developing countries, brand-generic substitution is not based on validated scientific evidence that confirm the therapeutic equivalence of the generic to the originator. Rather, decisions are made based on the availability of generic medications. Substitution by inappropriate preparations applies to antibiotics, which may increase the risk of resistance in case of underdosing. This analytical study aims to dose and assess for the accuracy of labeling three oral antibiotic preparations, namely ciprofloxacin hydrochloride, amoxicillin trihydrate and amoxicillin trihydrate-clavulanate potassium, the active pharmaceutical ingredients (APIs) found in brand and generic tablets available on the Lebanese market.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>One brand and 4 generics of ciprofloxacin tablets, 3 generic amoxicillin tablets, and 1 brand and 4 generics of amoxicillin-clavulanic acid medications, were quantified, taking 2 batches of each. According to the United States Pharmacopeia (USP) guidelines, ultra-high pressure liquid chromatography was used to measure the APIs content within tablets. The USP required assay limit of the API was taken as the main comparison criteria.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Out of the 5 ciprofloxacin medications tested, all 5 were out of the 2% required range, thus being substandard. For amoxicillin, all 3 medications were within the 20% range. As for amoxicillin-clavulanic acid medications, 4 out of 5 medications met the 30% required range of clavulanic acid and one exceeded the claimed amount of clavulanic acid, while all 5 met the assay limit for amoxicillin.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>These findings raise safety and efficacy concerns, providing solid grounds for potential correlations of antibiotic resistance\/substandard antibiotics.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40360-020-0390-y","type":"journal-article","created":{"date-parts":[[2020,2,22]],"date-time":"2020-02-22T13:02:45Z","timestamp":1582376565000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Are antibiotics substandard in Lebanon? Quantification of active pharmaceutical ingredients between brand and generics of selected antibiotics"],"prefix":"10.1186","volume":"21","author":[{"given":"Eva","family":"Hobeika","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"Farhat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Saab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walid","family":"Hleihel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samar","family":"Azzi-Achkouty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georges","family":"Sili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6918-5689","authenticated-orcid":false,"given":"Souheil","family":"Hallit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascale","family":"Salameh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,2,22]]},"reference":[{"issue":"9659","key":"390_CR1","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/S0140-6736(08)61762-6","volume":"373","author":"A Cameron","year":"2009","unstructured":"Cameron A, Ewen M, Ross-Degnan D, Ball D, Laing R. Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet. 2009;373(9659):240\u20139.","journal-title":"Lancet."},{"issue":"3","key":"390_CR2","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.healthpol.2012.04.015","volume":"106","author":"WA Kaplan","year":"2012","unstructured":"Kaplan WA, Ritz LS, Vitello M, Wirtz VJ. Policies to promote use of generic medicines in low and middle income countries: a review of published literature, 2000-2010. Health Policy. 2012;106(3):211\u201324.","journal-title":"Health Policy"},{"issue":"5","key":"390_CR3","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.jval.2012.04.004","volume":"15","author":"A Cameron","year":"2012","unstructured":"Cameron A, Mantel-Teeuwisse AK, Leufkens HG, Laing RO. Switching from originator brand medicines to generic equivalents in selected developing countries: how much could be saved? Value Health. 2012;15(5):664\u201373.","journal-title":"Value Health"},{"issue":"6","key":"390_CR4","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.jsps.2013.12.017","volume":"22","author":"MA Hassali","year":"2014","unstructured":"Hassali MA, Alrasheedy AA, McLachlan A, Nguyen TA, Al-Tamimi SK, Ibrahim MI, et al. The experiences of implementing generic medicine policy in eight countries: a review and recommendations for a successful promotion of generic medicine use. Saudi Pharm J. 2014;22(6):491\u2013503.","journal-title":"Saudi Pharm J"},{"key":"390_CR5","unstructured":"World Health Organization. The WHO health promotion glossary. https:\/\/www.who.int\/healthpromotion\/about\/HPG\/en\/. Updated 2013. Accessed 02 May 2019. 2013."},{"key":"390_CR6","unstructured":"Food U, Administration D. Approved drug products with therapeutic equivalence evaluations. In: Approved drug products with therapeutic equivalence evaluations: US Food and Drug Administration (FDA); 1985."},{"issue":"5","key":"390_CR7","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1177\/0091270006286436","volume":"46","author":"B Darpo","year":"2006","unstructured":"Darpo B, Nebout T, Sager PT. The international conference on harmonization of technical requirements for registration of Pharmaceuticals for Human use. J Clin Pharmacol. 2006;46(5):498\u2013507.","journal-title":"J Clin Pharmacol"},{"key":"390_CR8","unstructured":"Kopp S. WHO survey on terminology on \u201ccounterfeit\u201d medicines or equivalent. https:\/\/www.who.int\/medicines\/services\/counterfeit\/Surveyonterminology.pdf. Updated 2008. Accessed 02 May 2019."},{"issue":"5","key":"390_CR9","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1177\/2042098614543091","volume":"5","author":"MA Veronin","year":"2014","unstructured":"Veronin MA, Nutan MT, Dodla UK. Quantification of active pharmaceutical ingredient and impurities in sildenafil citrate obtained from the internet. Ther Adv Drug Saf. 2014;5(5):180\u20139.","journal-title":"Ther Adv Drug Saf"},{"issue":"1","key":"390_CR10","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1186\/s12889-018-6047-8","volume":"18","author":"M Ancillotti","year":"2018","unstructured":"Ancillotti M, Eriksson S, Veldwijk J, Nihlen Fahlquist J, Andersson DI, Godskesen T. Public awareness and individual responsibility needed for judicious use of antibiotics: a qualitative study of public beliefs and perceptions. BMC Public Health. 2018;18(1):1153.","journal-title":"BMC Public Health"},{"issue":"2","key":"390_CR11","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1111\/bcp.12298","volume":"78","author":"A Johnston","year":"2014","unstructured":"Johnston A, Holt DW. Substandard drugs: a potential crisis for public health. Br J Clin Pharmacol. 2014;78(2):218\u201343.","journal-title":"Br J Clin Pharmacol"},{"key":"390_CR12","volume-title":"Antibiotic resistance in lebanon","author":"P Salameh","year":"2017","unstructured":"Salameh P, Sacre H, Hallit S, Hajj A. Antibiotic resistance in lebanon. http:\/\/resistancecontrol.info\/2017\/antibiotic-resistance-in-lebanon\/. 2017."},{"key":"390_CR13","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/2047-2994-2-31","volume":"2","author":"A Huttner","year":"2013","unstructured":"Huttner A, Harbarth S, Carlet J, Cosgrove S, Goossens H, Holmes A, et al. Antimicrobial resistance: a global view from the 2013 world healthcare-associated infections forum. Antimicrob Resist Infect Control. 2013;2:31.","journal-title":"Antimicrob Resist Infect Control"},{"key":"390_CR14","volume-title":"Guidelines for the drug technical file submission: Module 3 and module 5","author":"Ministry of Public Health","year":"2017","unstructured":"Ministry of Public Health. Guidelines for the drug technical file submission: Module 3 and module 5. https:\/\/www.moph.gov.lb\/en\/Pages\/4\/6642\/quality-assurance-of-pharmaceutical-products. Accessed 02 May 2019. 2017."},{"issue":"1","key":"390_CR15","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1017\/S0007114516001665","volume":"116","author":"M Evans","year":"2016","unstructured":"Evans M, Salewski RP, Christman MC, Girard SA, Tompkins TA. Effectiveness of Lactobacillus helveticus and Lactobacillus rhamnosus for the management of antibiotic-associated diarrhoea in healthy adults: a randomised, double-blind, placebo-controlled trial. Br J Nutr. 2016;116(1):94\u2013103.","journal-title":"Br J Nutr"},{"key":"390_CR16","unstructured":"Ciprofloxacin hydrochloride. https:\/\/ncit.nci.nih.gov\/ncitbrowser\/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=NCI_Thesaurus&code=C47976. Updated 2019. Accessed 02 May 2019."},{"issue":"4","key":"390_CR17","first-page":"31","volume":"3","author":"A Alyahawi","year":"2018","unstructured":"Alyahawi A, Abdulmajed A. Quality control assessment of different brands of ciprofloxacin 500 mg tablets in Yemen. Univ J Pharm Res. 2018;3(4):31\u20136.","journal-title":"Univ J Pharm Res"},{"issue":"2","key":"390_CR18","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s00038-013-0493-y","volume":"59","author":"L Cheaito","year":"2014","unstructured":"Cheaito L, Azizi S, Saleh N, Salameh P. Assessment of self-medication in population buying antibiotics in pharmacies: a pilot study from Beirut and its suburbs. Int J Public Health. 2014;59(2):319\u201327.","journal-title":"Int J Public Health"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-020-0390-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40360-020-0390-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-020-0390-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,21]],"date-time":"2021-02-21T02:31:13Z","timestamp":1613874673000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-020-0390-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,22]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["390"],"URL":"https:\/\/doi.org\/10.1186\/s40360-020-0390-y","relation":{},"ISSN":["2050-6511"],"issn-type":[{"type":"electronic","value":"2050-6511"}],"subject":[],"published":{"date-parts":[[2020,2,22]]},"assertion":[{"value":"12 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval was not needed since no participants were involved in this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15"}}